# Joyce F. Liu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/joyce-f-liu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 19,097 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 62 |
| i10-index | 147 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5060953135 |
| ORCID iD | https://orcid.org/0000-0003-3888-3972 |
| Works | 559 |

## Researcher papers

- [Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/maintenance-olaparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/ovarian-cancer-version-2-2020-nccn-clinical-practice-guidelines-in-oncology/)
- [Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial](https://scholariq.org/papers/overall-survival-with-maintenance-olaparib-at-a-7-year-follow-up-in-patients/)
- [NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022](https://scholariq.org/papers/nccn-guidelines-insights-ovarian-cancer-version-3-2022/)
- [Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial](https://scholariq.org/papers/olaparib-and-specific-pi3k-inhibitor-alpelisib-for-patients-with-epithelial/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [DNA Repair Mechanisms](https://scholariq.org/topics/dna-repair-mechanisms/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.